HealthDay News — For patients with acute ischemic stroke, treatment with stent retrievers with quick reperfusion time is associated with improved outcomes, according to a study published in Radiology.
Mayank Goyal, MD, from the University of Calgary in Canada, and colleagues examined the correlation between functional independence and time to reperfusion in the Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial. One hundred ninety-six patients with disabling acute ischemic stroke were enrolled; patients were treated with intravenous tissue plasminogen activator alone or in combination with the Solitaire device.
The researchers found that a symptom onset to reperfusion time of 150 minutes in the stent retriever arm of the study correlated with a 91% estimated probability of functional independence, which decreased by 10 and 20% over the next hour and with every subsequent hour of delay, respectively. The time from arrival at the emergency department to arterial access and time to reperfusion were 90 and 129 minutes, respectively. Longer symptom onset to groin puncturing timing was seen for patients who initially arrived at a referring facility versus those who presented directly to the endovascular-capable center (P < 0.001).
“Fast reperfusion leads to improved functional outcome among patients with acute stroke treated with stent retrievers,” the authors write.
Several authors disclosed financial ties to pharmaceutical and medical devices companies, including Covidien, which funded the SWIFT PRIME trial.
Goyal M, Jadhav AP, Bonafe A, et al. Analysis of Workflow and Time to Treatment and the Effects on Outcome in Endovascular Treatment of Acute Ischemic Stroke: Results from the SWIFT PRIME Randomized Controlled Trial. Radiology. 2016; doi:10.1148/radiol.2016160204.